As market factors drive the rapid growth of decentralized clinical trials, organizations should embrace risk-based quality management to evaluate the new dimensions of risk and ensure effective oversight of disparate data sources, writes John Hall.
John Hall
Advertisement
SVP, EMEA & APAC, CluePoints
Articles by John Hall
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
AI in Action: Breaking Down Clinical Trial Bottlenecks
2
Unlocking the Potential of Agentic AI to Reduce Trial Delays
3
Balancing Human Oversight and Automation in AI-Driven Trials
4
2025 SCRS Global Site Solutions Summit: How Standardized CDAs Can Accelerate Site Activation
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
